WO1985005031A1 - A method for the modulation of the immune response - Google Patents
A method for the modulation of the immune response Download PDFInfo
- Publication number
- WO1985005031A1 WO1985005031A1 PCT/AU1985/000101 AU8500101W WO8505031A1 WO 1985005031 A1 WO1985005031 A1 WO 1985005031A1 AU 8500101 W AU8500101 W AU 8500101W WO 8505031 A1 WO8505031 A1 WO 8505031A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- amphiphile
- animal
- modify
- immune response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
Definitions
- This invention relates to a method of modulating the immune response in an animal (which term as used throughout this specification includes a human), and to compositions for use in the performance of such a method.
- An animal's immune system is comprised of numerous elements that act separately and/or in concert to counteract, to eliminate, or to neutralise substances that are recognised by that system as foreign to the animal host.
- the substance recognised as foreign by the immune system has its origin exogenous to the host.
- exogenous substances are infectious bacteria and the by-products of their cellular activity, virus particles and their proteins, proteins injected by insect stings, and the like.
- autoimmune diseases such as rheumatoid arthritis
- the host's immune system recognises host-made proteins or self-made proteins as foreign.
- the immune response can be modified by artificial suppression (immunosuppression) or enhancement (immunopotentiation).
- Immunosuppression i.e., artificially induced decreased responsiveness, can be achieved by six general methods: (1) administration of antigen, (2) administration of specific antisera or antibody, (3) use of other biologic reagents such as antilymphocyte antisera, (4) use of drugs or hormones, (5) radiation, and (6) surgical removal of lymphoid tissue.
- Immunopotentiation can include the administration of an agent effecting an increase in the rate at which the immune response develops, an increase in the intensity or level of the response, a prolongation of the response, of the development of a response to an otherwise non-immunogenic substance.
- agents which are known to enhance immune responses are generally termed adjuvants and can be placed into two general categories: (1) those providing general potentiation, i.e., substances which enhance both cellular and humoral immune responses for a wide variety of antigens, and (2) those providing specific potentiation, i.e., substances which enhance specific responses to certain antigens only.
- immunosuppressive drugs that have been developed to manipulate the immune response, are usually compounds of complex structure that have been discovered by accident. Further, their mode of action is often unknown or very unpredictable and administration of the drugs can be accompanied by undesirable side-effects.
- a second object is to provide a method of modulating the immune response of an animal in which the active site of the substances used to modulate the immune response can readily be determined and easily altered to modify that immune response.
- a third object is to provide a method of modulating the immune response without undesired side-effects.
- amphiphiles There exists a class of compounds called “amphiphiles”.
- the structure of these compounds comprises two dissimilar portions - a nonpolar, hydrophobia (repelled by water) "tail” portion which is lyophilic (attracted to fats) and often a hydrocarbon chain, and a polar, hydrophilic and lyophobic "head” portion.
- Many amphiphiles are commonly used as detergents.
- Detergents dissolve fatty materials and dirt by forming micelles, in which the oil or fat is at the centre of a sphere formed by the nonpolar hydrocarbon ends.
- the polar groups form a hydrophilic surface around the sphere and render the entire micelle water-soluble.
- the present invention is based on the discovery that the nonpolar or tail end of certain amphiphiles can embed into the surface of a cell without necessarily destroying cell membrane function.
- the polar or head group of the amphiphile now a part of the surface of the cell, modifies the local environment and thus alters the acceptor sites on the surface of that cell.
- local membrane curvature and thickness are perturbed, again modifying local microenvironment of cell attached peripheral molecules involved in immunorecognition.
- a method of modulating or suppressing the immune response of an animal which comprises the administration of an effective amount of at least one amphiphile which is capable of interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell.
- amphiphile (s) may be administered in association with a pharmaceutically acceptable carrier or diluent.
- the amphiphile is administered at a concentration which is less than the concentration at which the cell membrane is disrupted and the cell lysed.
- composition suitable for modulation or suppression of the immune response of an animal which composition comprises at least one amphiphile as described above together with a pharmaceutically acceptable carrier or diluent.
- this invention relates to the use of at least one amphiphile as described above for the modulation or suppression of the immune response of an animal, and to the use of at least one amphiphile as described above for the production of a composition for use in the modulation or suppression of the immune response of an animal.
- the present invention also extends to a method of preparing animal tissue for grafting or transplantation from a donor animal to a recipient animal, which method comprises the treatment of animal tissue from said donor animal with an effective amount of at least one amphiphile as described above to inactivate cells in said tissue which stimulate the graft rejection reaction.
- graft tissues removed from a donor animal such as small cell grafts, (for example, endocrine tissues), may be exposed in vitro to the action of an amphiphile in accordance with this invention prior to being grafted into the recipient animal.
- amphiphiles used in the present invention are cationic surfactants of the general formulae: R 1 R 2 X
- R 1 represents a straight- or branched-chain, saturated or unsaturated hydrocarbon of at least 8 carbon atoms
- R 2 represents a straight- or branched-chain, saturated or unsaturated hydrocarbon of at least 8 carbon atoms; and X represents any suitable cationic moiety required to product an amphiphile; or
- R 3 represents a straight- or branched chain, saturated or unsaturated hydrocarbon of at least 14 carbon atoms
- X is as defined above.
- R 1 and R 2 are chosen so that the total number of carbon atoms in the combined chains is 24 or fewer, or R 3 is chosen to have at least 16 carbon atoms in the chain.
- combinations of R 1 and R 2 include C 12 C 12 ,
- R 3 is typically C 16 .
- the present invention also extends to the use of mixtures of amphiphiles as broadly described above, including mixtures of double-chained amphiphiles of the formula R 1 R 2 X with single-chained amphiphiles of the formula R 3 X.
- single- and double-chained cationic surfactants encompassed within the present invention exert their immunosuppressive effects by different mechanisms. Addition of single-chained surfactants to a cell-culture, or in vivo, will not destroy cell membranes, i.e. exhibit cell toxicity, and will exhibit immunosuppression below the critical micelle concentration (CMC), however they will be toxic above the CMC at which point spontaneous vesicles form and cell lysis occurs. Double-chained surfactants on the other hand form vesicles rather than micelles and do not have a well-defined CMC, and it has been observed that such surfactants do not destroy cell membranes.
- CMC critical micelle concentration
- Particularly potent immunosuppressants are double-chained quaternary ammonium surfactants within this preferred class, more particularly didoecyldimethylammonium bromide (DDAB) and didodecyldimethylammonium acetate (DDAA).
- DDAB didoecyldimethylammonium bromide
- DDAA didodecyldimethylammonium acetate
- the immunosuppressive activity of cationic surfactants has been tested by a study of the effect on the cell-mediated immune response, which provides a good model of cell/cell interactions.
- the results of this study which are set out in detail below, have established that the immunosuppressive effect of these surfactants is not due to non-specific toxicity, but is probably due to impaired T-cell function.
- Figure 1 shows lysis of P815 target cells by alloreactive B6 T c cells generated in vitro in the presence of various concentrations of DDAB.
- Figure 2 shows mortality of BALB/c female mice treated with 2 consecutive injections of 200 ⁇ g DDAB i.v. ( ⁇ ) compared to saline treated controls (o), after challenge with 2 x 10 5 pfu MCMV i.p.
- Figure 3 shows increase in footpad thickness of BALB/ ⁇ female mice after injection of 3 x 10 6 T c cells reactive against H-2 d alloantigens. Recipients were treated either with 2 consecutive injections of 200 ⁇ g DDAB i.v. ( ⁇ ), or 2 mg in olive oil sc ( ⁇ ). Controls (o) treated with saline or olive oil were not significantly different from each other, and were pooled for analysis. Each point represents the mean of a minimum of 5 mice. After 24 hr., footpad swelling in all mice treated with DDAB was significantly less than in the controls (p ⁇ 0.05). The vertical bars represent the standard deviations of the means.
- Figure 4 shows lysis of P815 target cells by alloreactive B6 T cells generated in vitro in the presence of 10 ng/ml of DDAB ( ⁇ ) or DDAA ( ⁇ ). Control (o).
- Figure 5 shows lysis of P815 target cells by alloreactive B6 T c cells generated in the presence of DDAA or cyclosporin A(CsA).
- Figure 6 shows lysis of P815 target cells by alloreactive B6 T c cells generated in the presence of various single- and double-chained cationic surfactants.
- mice BALB/c and C57 B1/6J (B6) mice were obtained from the Animal Breeding Establishment at the John Curtin School of Medical Research. Only female mice 6-12 weeks old were used in experiments.
- DDAB Didodecyl dimethyl ammonium bromide
- DDAA acetate
- the former was purchased originally from Eastman Kodak and recrystallised twice from acetonitrile, the latter made by ion exchange to the hydroxide form in CO 2 free conditions, followed by neutralisation with acetic acid and lyphilisation.
- the bromide and acetate were used in saline suspension at 1 mg/ml; the bromide additionally in olive oil at 10 mg/ml. All preparations were sonicated to clear vesicular suspensions at 70 watts for two minutes before use.
- Murine cytomegalovirus was grown in the salivary glands of 4-6 week old female BALB/c mice and stored at -70°C until used. Titres were determined by plaqueing on BALB/c mouse embryo fibroblasts.
- T c Cells reactive against BALB/c (H-2 d ) alloantigens were obtained by culturing B6 spleen cells (2 x 10 6 /ml) with irradiated (2000R) BALB/c spleen cells (5 x 10 5 /ml) in Eagles Minimum Essential Medium supplemented with 5% foetal calf serum and 10 -4 M 2-mercaptoethanol. In certain experiments, appropriate concentrations of the surfactant were added at the initiation of the culture.
- the cells were harvested, resuspended in 0.5 ml of the medium, and lytic activity assayed on 51 Cr - labelled P815 (H-2 d ) target cells.
- lytic activity assayed on 51 Cr - labelled P815 (H-2 d ) target cells.
- a linear regression analysis was performed on the number of viable cells versus percent lysis at each dilution of the original culture. The results were then expressed as percent lysis at a specified effector-to-target cell ratio.
- DDAA 18.2 1 Surfactants were added to the culture at a concentration of 10ng/ml.
- FIG. 5 shows lysis of P815 target cells by alloreactive B6 T cells generated in the presence of 1 ⁇ g/ml CSA ( ⁇ ) 100 ng/ml CsA ( ⁇ ), 10 ng/ml CsA ( ⁇ ), 1 ⁇ g/ml DDAA , 100 ng/ml DDAA ( ⁇ ) , and 10 ng/ml DDAA ( ), Control (o).
- a surfactant with a single chain C 16 Br and surfactants with chains of unequal length, such as C 8 C 12 Br and C 8 C 16 Br partly suppress T lymphocyte responses in vitro whereas another single chained surfactant C 12 Br and other double-chained surfactants with slightly longer chains such as C 12 C 18 Ac or (C 16 ) 2 Ac are relatively inactive.
- Figure 6 shows lysis of P815 target cells by alloreactive B6 T c cells generated in the presence of 100ng/ml C 16 Br ( ⁇ ), 100ng/ml C 8 C 12 Br ( ⁇ ), 100ng/ml C 12 Br ( ⁇ ), 200ng/ml C 12 C 18 Ac ( ⁇ ) and 200ng/ml (C 16 ) 2 Ac ( , Control (o).
Abstract
A method of modulating or suppressing the immune response of an animal comprises the administration of an effective amount of at least one amphiphile which is capable of interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell. A method of preparing animal tissue for grafting or transplantation from a donor animal to a recipient animal, and immunosuppressant compositions, are also disclosed. Preferably, the amphiphile is a cationic surfactant, such as a double-chained quarternary ammonium surfactant.
Description
A METHOD FOR THE MODULATION OP THE IMMUNE RESPONSE
This invention relates to a method of modulating the immune response in an animal (which term as used throughout this specification includes a human), and to compositions for use in the performance of such a method.
An animal's immune system is comprised of numerous elements that act separately and/or in concert to counteract, to eliminate, or to neutralise substances that are recognised by that system as foreign to the animal host. Generally, but not necessarily, the substance recognised as foreign by the immune system has its origin exogenous to the host. Exemplary of such exogenous substances are infectious bacteria and the by-products of their cellular activity, virus particles and their proteins, proteins injected by insect stings, and the like. In autoimmune diseases, such as rheumatoid arthritis, the host's immune system recognises host-made proteins or self-made proteins as foreign.
The immune response can be modified by artificial suppression (immunosuppression) or enhancement (immunopotentiation). Immunosuppression, i.e., artificially induced decreased responsiveness, can be achieved by six general methods: (1) administration of antigen, (2) administration of specific antisera or
antibody, (3) use of other biologic reagents such as antilymphocyte antisera, (4) use of drugs or hormones, (5) radiation, and (6) surgical removal of lymphoid tissue. Immunopotentiation can include the administration of an agent effecting an increase in the rate at which the immune response develops, an increase in the intensity or level of the response, a prolongation of the response, of the development of a response to an otherwise non-immunogenic substance. The agents which are known to enhance immune responses are generally termed adjuvants and can be placed into two general categories: (1) those providing general potentiation, i.e., substances which enhance both cellular and humoral immune responses for a wide variety of antigens, and (2) those providing specific potentiation, i.e., substances which enhance specific responses to certain antigens only.
To date, immunosuppressive drugs that have been developed to manipulate the immune response, are usually compounds of complex structure that have been discovered by accident. Further, their mode of action is often unknown or very unpredictable and administration of the drugs can be accompanied by undesirable side-effects.
It is a first object of the present invention to provide a method of modulating, and particularly of suppressing the immune response of an animal. A second object is to provide a method of modulating the immune response of an animal in which the active site of the substances used to modulate the immune response can readily be determined and easily altered to modify that immune response. A third object is to provide a method
of modulating the immune response without undesired side-effects. Other aims and objects of the present invention will become apparent from the following description.
There exists a class of compounds called "amphiphiles". The structure of these compounds comprises two dissimilar portions - a nonpolar, hydrophobia (repelled by water) "tail" portion which is lyophilic (attracted to fats) and often a hydrocarbon chain, and a polar, hydrophilic and lyophobic "head" portion. Many amphiphiles are commonly used as detergents. Detergents dissolve fatty materials and dirt by forming micelles, in which the oil or fat is at the centre of a sphere formed by the nonpolar hydrocarbon ends. The polar groups form a hydrophilic surface around the sphere and render the entire micelle water-soluble.
The present invention is based on the discovery that the nonpolar or tail end of certain amphiphiles can embed into the surface of a cell without necessarily destroying cell membrane function. The polar or head group of the amphiphile, now a part of the surface of the cell, modifies the local environment and thus alters the acceptor sites on the surface of that cell. In addition, local membrane curvature and thickness are perturbed, again modifying local microenvironment of cell attached peripheral molecules involved in immunorecognition.
According to the present invention, there is provided a method of modulating or suppressing the immune response of an animal, which comprises the
administration of an effective amount of at least one amphiphile which is capable of interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell.
If desired, the amphiphile (s) may be administered in association with a pharmaceutically acceptable carrier or diluent.
In performing the method of this aspect of the invention, the amphiphile is administered at a concentration which is less than the concentration at which the cell membrane is disrupted and the cell lysed.
In another aspect of this invention, there is provided a composition suitable for modulation or suppression of the immune response of an animal, which composition comprises at least one amphiphile as described above together with a pharmaceutically acceptable carrier or diluent.
In yet another aspect, this invention relates to the use of at least one amphiphile as described above for the modulation or suppression of the immune response of an animal, and to the use of at least one amphiphile as described above for the production of a composition for use in the modulation or suppression of the immune response of an animal.
The present invention also extends to a method of preparing animal tissue for grafting or transplantation from a donor animal to a recipient animal, which method comprises the treatment of animal
tissue from said donor animal with an effective amount of at least one amphiphile as described above to inactivate cells in said tissue which stimulate the graft rejection reaction.
In particular, graft tissues removed from a donor animal, such as small cell grafts, (for example, endocrine tissues), may be exposed in vitro to the action of an amphiphile in accordance with this invention prior to being grafted into the recipient animal.
Amphiphiles, and particularly cationic surfactants closely related to those in widespread household and commercial use, have been shown to inhibit the generation of mixed lymphocyte reactions in vitro; to inhibit inflammatory responses caused by the injection of alloreactive cytotoxic cells into the footpads of mice; and to increase the susceptibility of mice to murine cytomegalovirus. This work confirms the potent immunosuppressive activity of these cationic surfactants.
Preferably, the amphiphiles used in the present invention are cationic surfactants of the general formulae: R1R2X
wherein R1 represents a straight- or branched-chain, saturated or unsaturated hydrocarbon of at least 8 carbon atoms;
R2 represents a straight- or branched-chain, saturated or unsaturated hydrocarbon of at least 8 carbon atoms; and
X represents any suitable cationic moiety required to product an amphiphile; or
R3X
wherein R3 represents a straight- or branched chain, saturated or unsaturated hydrocarbon of at least 14 carbon atoms; and
X is as defined above.
In particularly preferred embodiments, R1 and R2 are chosen so that the total number of carbon atoms in the combined chains is 24 or fewer, or R3 is chosen to have at least 16 carbon atoms in the chain. Typically, combinations of R1 and R2 include C12C12,
C8C12 and C8C16, whilst R3 is typically C16.
The present invention also extends to the use of mixtures of amphiphiles as broadly described above, including mixtures of double-chained amphiphiles of the formula R1R2X with single-chained amphiphiles of the formula R3X.
It has been observed that the single- and double-chained cationic surfactants encompassed within the present invention exert their immunosuppressive effects by different mechanisms. Addition of single-chained surfactants to a cell-culture, or in vivo, will not destroy cell membranes, i.e. exhibit cell toxicity, and will exhibit immunosuppression below the critical micelle concentration (CMC), however they will be toxic above the CMC at which point spontaneous vesicles form and cell lysis occurs. Double-chained
surfactants on the other hand form vesicles rather than micelles and do not have a well-defined CMC, and it has been observed that such surfactants do not destroy cell membranes. Immunosuppression with these surfactants is not exhibited at longer chain lengths where the chain melting temperature is so high that aggregates are frozen lamellar phase inaccessible to cell membranes, i.e. the chain melting temperature of the surfactant should be in the range of 37-40°C or below for immunosuppression to be exhibited.
Particularly potent immunosuppressants, both in vivo and in vitro, are double-chained quaternary ammonium surfactants within this preferred class, more particularly didoecyldimethylammonium bromide (DDAB) and didodecyldimethylammonium acetate (DDAA).
The immunosuppressive activity of cationic surfactants has been tested by a study of the effect on the cell-mediated immune response, which provides a good model of cell/cell interactions. The results of this study, which are set out in detail below, have established that the immunosuppressive effect of these surfactants is not due to non-specific toxicity, but is probably due to impaired T-cell function.
The immunosuppressive activity of cationic surfactants is illustrated in the accompanying figures, in which: Figure 1 shows lysis of P815 target cells by alloreactive B6 Tc cells generated in vitro in the presence of various concentrations of DDAB. (o) control; (●) 1 μg/ml; (Δ) 100 ng/ml; (▲) 10 ng/ml.
Figure 2 shows mortality of BALB/c female mice treated with 2 consecutive injections of 200μg DDAB i.v. (●) compared to saline treated controls (o), after challenge with 2 x 105 pfu MCMV i.p.
Figure 3 shows increase in footpad thickness of BALB/σ female mice after injection of 3 x 106 Tc cells reactive against H-2d alloantigens. Recipients were treated either with 2 consecutive injections of 200μg DDAB i.v. (Δ), or 2 mg in olive oil sc (▲). Controls (o) treated with saline or olive oil were not significantly different from each other, and were pooled for analysis. Each point represents the mean of a minimum of 5 mice. After 24 hr., footpad swelling in all mice treated with DDAB was significantly less than in the controls (p < 0.05). The vertical bars represent the standard deviations of the means.
Figure 4 shows lysis of P815 target cells by alloreactive B6 T cells generated in vitro in the presence of 10 ng/ml of DDAB (Δ) or DDAA (▲). Control (o).
Figure 5 shows lysis of P815 target cells by alloreactive B6 Tc cells generated in the presence of DDAA or cyclosporin A(CsA).
Figure 6 shows lysis of P815 target cells by alloreactive B6 Tc cells generated in the presence of various single- and double-chained cationic surfactants.
EXAMPLE 1
(i) Materials and Methods
Mice: BALB/c and C57 B1/6J (B6) mice were obtained from the Animal Breeding Establishment at the John Curtin School of Medical Research. Only female mice 6-12 weeks old were used in experiments.
Surfactants: Didodecyl dimethyl ammonium bromide (DDAB) and acetate (DDAA) were a gift from Dr. D.F.Evans, Department of Chemical Engineering, University of Minnesota. The former was purchased originally from Eastman Kodak and recrystallised twice from acetonitrile, the latter made by ion exchange to the hydroxide form in CO2 free conditions, followed by neutralisation with acetic acid and lyphilisation. The bromide and acetate were used in saline suspension at 1 mg/ml; the bromide additionally in olive oil at 10 mg/ml. All preparations were sonicated to clear vesicular suspensions at 70 watts for two minutes before use.
Virus: Murine cytomegalovirus (MCMV) was grown in the salivary glands of 4-6 week old female BALB/c mice and stored at -70°C until used. Titres were determined by plaqueing on BALB/c mouse embryo fibroblasts.
Preparation of alloreactive Cytotoxic T (Tc) Cells: Cells reactive against BALB/c (H-2d) alloantigens were obtained by culturing B6 spleen cells (2 x 106/ml) with irradiated (2000R) BALB/c spleen cells (5 x 105/ml) in Eagles Minimum Essential Medium supplemented with 5% foetal calf serum and 10 -4 M 2-mercaptoethanol. In
certain experiments, appropriate concentrations of the surfactant were added at the initiation of the culture. At the conclusion of the 5 day culture period, the cells were harvested, resuspended in 0.5 ml of the medium, and lytic activity assayed on 51Cr - labelled P815 (H-2d) target cells. In order to determine the lysis per cell, a linear regression analysis was performed on the number of viable cells versus percent lysis at each dilution of the original culture. The results were then expressed as percent lysis at a specified effector-to-target cell ratio.
Graft-Versus-Host Response: Alloreactive Tc cells prepared as above were washed once, resuspended in Puck's balanced salt solution, and 3 x 106 cells in 40μl injected into the left footpads of BALB/c mice that had previously been treated with DDAB. An equal volume of Puck's saline alone was injected into the other footpad as a control. At various intervals thereafter, swelling was measured using a dial gauge caliper (H.C. Kroplin, Schluchtern, Hessen, FGR). The results were expressed as the difference in thickness between left and right footpads.
(ii) Results
Initial experiments were designed to investigate the effect of DDAB on alloreactive Tc cells, either generated or assayed in the presence of the surfactant. Fig.1 shows that there was substantial loss of effector cell activity in the cultures, even at concentrations as low as 10 nanograms/ml. However, because DDAB was toxic to lymphocytes when used at 1μ/ml, the yields of cells from the cultures were reduced at lower concentrations
of the surfactant, it was essential to determine whether the apparent immunosuppressive effect was simply due to the presence of proportionally fewer effector cells. This possibility can be dismissed. When the data were corrected for lysis on a cell-for-cell basis (Table 1) it was clear that effector cell function had indeed been impaired. In contrast, when the T cell activity of control cultures was assayed in the presence of similar concentrations of DDAB, there was no loss of effector cell function (data not shown).
TABLE 1 Corrected lysis of P815 target cells by alloreactive B6 cells generated in the presence of various concentrations of didodecyl dimethyl ammonium bromide
Treatment Percent lysis1
None 74.3
2 1μg/ml 0
100μg/ml 36.8
10ng/ml 33.0 1 Calculated from linear regressions, at a killer-to-target ratio of 2.5:1 2 No viable cells were recovered from the culture.
Given the above, it was important to establish whether the result could be attributed to some singularity of the tissue culture system, or whether the surfactant also had some biological activity in vivo. In order to discriminate between these alternatives, BALB/c mice treated with two consecutive injections of
DDAB i.v. were challenged with a minimum lethal dose (2 x 105 pfu) of MCMV. These mice showed a sharp reduction in median survival time compared to infected mice pretreated with saline (Fig.2). Because anti-viral Tc cells are essential for recovery from primary viral infection, an increased susceptibility to MCMV infection was consistent with the impaired generation of Tc cell function obsereved in vitro. A further experiment was devised to examine the function of alloreactive T cells, generated in vitro, after transfer into DDAB treated mice. The reactivity of these cells, as measured by the increase in footpad swelling, was substantially reduced (Fig.3). These in vivo phenomena depend not only on effector cell function, but also on movement of T lymphocytes and other cell types from the blood to the site of antigenic challenge. As cell recirculation patterns could also be disrupted by the presence of a surfactant, the precise mechanism(s) of action must await further analysis.
Attempts to determine whether intranasal administration of DDAB would also cause generalised immunosuppression were unsuccessful because at the dose used (50μg) the surfactant apparently interfered directly with lung function, and the mice died within 24 hr.
The marked immunosuppressive potential exhibited by DDAB both in vitro and in vivo is manifest. It was of interest to enquire further if the mode of delivery of surfactant vesicles altered these biological effects. Sonicated DDAB suspensions form small (diameter = 500 A) cationic vesicles admixed with liquid crystallites which in the presence of saline further flocculate to increase
the proportion of less accessible liquid crystals. By contrast, using acetates or other carboxylates as counterions, vesicles and micelles form spontaneously in aqueous solution, and in saline revert to liquid crystals much more slowly. The expectation was then that this circumstance would result in a freer passage of surfactant molecules into the cell membrane by heterocoagulation. The relative effects of the two salts on the generation of alloreactive cells in vitro is shown in Fig.4 and the results are in accord with prediction. Tc cells cultured in the presence of DDAA showed less effector activity than those grown in the presence of the bromide and this difference was even more apparent when adjustment was made to compensate for different cell yields (Table 2). Vesicles made by polymerising the counterions should be even more effective, and have the virtue of enabling simultaneous delivery of encapsulated additional agents.
TABLE 2
Corrected lysis of P815 target cells by alloreactive B6 cells generated in the presence of didodecyl dimethyl ammonium bromide or acetate
Treatment1 Percent lysis2
None 45.9
DDAB 38.1
DDAA 18.2 1 Surfactants were added to the culture at a concentration of 10ng/ml.
2 Calculated from linear regressions, at a killer-to-target cell ratio of 5:1.
EXAMPLE 2
The potency of the immunosuppressive effects of DDAA have been compared with those of cyclosporin A (CsA) dissolved in dimethylsulphoxide. The materials and methods used were based on those described for Example 1 above. Figure 5 shows lysis of P815 target cells by alloreactive B6 T cells generated in the presence of 1 μg/ml CSA (●) 100 ng/ml CsA (Δ), 10 ng/ml CsA (□), 1 μg/ml DDAA
, 100 ng/ml DDAA (♢ ) , and 10 ng/ml DDAA (
), Control (o).
A surfactant with a single chain C16Br and surfactants with chains of unequal length, such as C8C12Br and C8C16Br partly suppress T lymphocyte responses in vitro whereas another single chained surfactant C12Br and other double-chained surfactants with slightly longer chains such as C12C18Ac or (C16)2Ac are relatively inactive. Figure 6 shows lysis of P815 target cells by alloreactive B6 Tc cells generated in the presence of 100ng/ml C16Br (□), 100ng/ml C8C12Br (Δ), 100ng/ml C12Br (■), 200ng/ml C12C18Ac (●) and 200ng/ml (C16)2Ac (
, Control (o).
Claims
1. A method of modulating or suppressing the immune response of an animal, which comprises the administration of an effective amount of at least one amphiphile which is capable of interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell.
2. A method according to claim 1 wherein the amphiphile is administered in association with a pharmaceutically acceptable carrier or diluent.
3. A method according to claim 1 or claim 2 wherein the amphiphile is administered at a concentration which is less than the concentration at whhich the cell membrane is disrupted and the cell lysed.
4. A composition suitable for modulation or suppression of the immune response of an animal, which composition comprises at least one amphiphile which is capable of interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell, together with a pharmaceutically acceptable carrier or diluent.
5. The use of at least one amphiphile which is capable of interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell, for the modulation or suppression of the immune response of an animal.
6. The use of at least one amphiphile which is capable of interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell, for the production of a composition for use in the modulation or suppression of the immune response of an animal.
7. A method of preparing animal tissue for grafting or transplantation from a donor animal to a recipient animal, which method comprises the treatment of animal tissue from said donor animal with an effective amount of at least one amphiphile which is capable of interacting at the surface of a cell to modify the surface properties thereof so as to inhibit or modify recognition of an antigen by the altered cell, to inactivate cells in said tissue which stimulate the graft rejection reaction.
8. A method, composition or use according to any one of claims 1 to 7 wherein the amphiphile is a compound of the general formula
RXR2X wherein R1 represents a straight- or branched-chain, saturated or unsaturated hydrocarbon of at least 8 carbon atoms; R2 represents a straight- or branched-chain, saturated or unsaturated hydrocarbon of at least 8 carbon atoms; and X represents any suitable cationic moiety required to produce an amphiphile; or
R3X wherein R3 represents a straight- or branched-chain, saturated or unsaturated hydrocarbon of at least 14 carbon atoms; and X is as defined above.
9. A method, compositon or use according to claim 8 wherein R1 and R2 are chosen so that the total number of carbon atoms in the combined chains is 24 or fewer, or wherein R3 is chosen to have at least 16 carbon atoms in the chain.
10. A method, composition or use according to any one of claims 1 to 9 wherein said amphiphile is a double-chained quarternary ammonium surfactant.
11. A method, compositon or use according to claim 10 wherein said double-chained quarternary ammonium surfactant is didodecyldimethylammonium bromide, or didodecyldimethylammonium acetate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPG4895 | 1984-05-09 | ||
AUPG489584 | 1984-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1985005031A1 true WO1985005031A1 (en) | 1985-11-21 |
Family
ID=3770607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1985/000101 WO1985005031A1 (en) | 1984-05-09 | 1985-05-08 | A method for the modulation of the immune response |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0181351A4 (en) |
JP (1) | JPS61502124A (en) |
WO (1) | WO1985005031A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963557A (en) * | 1987-09-28 | 1990-10-16 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
WO1992022294A1 (en) * | 1991-06-07 | 1992-12-23 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
WO1994016686A1 (en) * | 1993-01-27 | 1994-08-04 | Naturwissenschaftliches Und Medizinisches Institut An Der Universität Tübingen In Reutlingen | Wide spectrum antiviral chemotherapeutic agent and use thereof |
US5358944A (en) * | 1990-09-19 | 1994-10-25 | American Home Products Corporation | Rapamycin esters for treating transplantation rejection |
US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
US5434160A (en) * | 1992-11-18 | 1995-07-18 | Lilly Industries Limited | Pyrano[3,2-h]quinolines for treating restenosis |
US5591748A (en) * | 1991-06-07 | 1997-01-07 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
US6121270A (en) * | 1992-12-16 | 2000-09-19 | Cell Therapeutics, Inc. | Epoxide-containing compounds |
US6858623B2 (en) * | 2000-09-08 | 2005-02-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cysteine proteases |
US7417031B2 (en) * | 1997-11-11 | 2008-08-26 | Takara Bio Inc. | Use of algae-derived physiologically active substances for treating a carcinomatous disease |
US7648966B2 (en) * | 2003-05-20 | 2010-01-19 | Pharmaxis Pty Limited | Mannose-6-phosphonate compounds for the treatment of inflammatory diseases |
US20100104590A1 (en) * | 2006-12-30 | 2010-04-29 | Snu R&Db Foundation | Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient |
US7935672B2 (en) * | 2004-03-11 | 2011-05-03 | Michel Prost | Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same |
US8541182B2 (en) | 2004-12-02 | 2013-09-24 | Can-Fite Biopharma Ltd. | Biological marker for inflammation |
US8557794B2 (en) * | 2003-10-24 | 2013-10-15 | N.V. Nutricia | Immunemodulating oligosaccharides |
US8722645B2 (en) | 2006-05-16 | 2014-05-13 | Galectin Therapeutics Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
US8871925B2 (en) * | 2011-12-28 | 2014-10-28 | Galectin Therapeutics Inc. | Compositions of novel carbohydrate drug for treatment of human diseases |
US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
US9763974B2 (en) | 2012-06-06 | 2017-09-19 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
US9872909B2 (en) | 2012-09-17 | 2018-01-23 | Galeotin Therapeutics, Inc. | Method for enhancing specific immunotherapies in cancer treatment |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2653156A (en) * | 1949-06-21 | 1953-09-22 | Lehn & Fink Products Corp | Quaternary ammonium compounds and process for producing the same |
AU3825368A (en) * | 1967-05-25 | 1969-11-27 | Dermal Laboratories, Ltd | New composition for the treatment of warts |
AU5477373A (en) * | 1972-05-01 | 1974-10-24 | Environmental Science Corporation | Method and composition for the control of fertility |
US3950541A (en) * | 1971-09-20 | 1976-04-13 | Waldstein David A | Aqueous compositions containing quaternary ammonium salts for treatment of rectal itching and lessening of irritation and swelling of prolapsed and of irritated and swollen external hemorrhoids |
US4320147A (en) * | 1980-05-09 | 1982-03-16 | Lonza Inc. | Disinfectant composition and the use thereof |
US4330551A (en) * | 1980-08-26 | 1982-05-18 | Synergetics Co. | Therapeutic method |
US4450174A (en) * | 1982-05-27 | 1984-05-22 | Millmaster Onyx Group, Inc. | Decyl quaternary ammonium compounds |
-
1985
- 1985-05-08 WO PCT/AU1985/000101 patent/WO1985005031A1/en not_active Application Discontinuation
- 1985-05-08 JP JP50205585A patent/JPS61502124A/en active Pending
- 1985-05-08 EP EP19850901941 patent/EP0181351A4/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2653156A (en) * | 1949-06-21 | 1953-09-22 | Lehn & Fink Products Corp | Quaternary ammonium compounds and process for producing the same |
AU3825368A (en) * | 1967-05-25 | 1969-11-27 | Dermal Laboratories, Ltd | New composition for the treatment of warts |
US3950541A (en) * | 1971-09-20 | 1976-04-13 | Waldstein David A | Aqueous compositions containing quaternary ammonium salts for treatment of rectal itching and lessening of irritation and swelling of prolapsed and of irritated and swollen external hemorrhoids |
AU5477373A (en) * | 1972-05-01 | 1974-10-24 | Environmental Science Corporation | Method and composition for the control of fertility |
US4320147A (en) * | 1980-05-09 | 1982-03-16 | Lonza Inc. | Disinfectant composition and the use thereof |
US4330551A (en) * | 1980-08-26 | 1982-05-18 | Synergetics Co. | Therapeutic method |
US4450174A (en) * | 1982-05-27 | 1984-05-22 | Millmaster Onyx Group, Inc. | Decyl quaternary ammonium compounds |
Non-Patent Citations (1)
Title |
---|
Japanese Journal of Medical Science & Biology, Volume 31, No. 4, issued 1978 August (Tokyo, Japan), J. CHIBA and Y. EGASHIRA, 'Adjuvant Effect of Cationic Surface-Active Lipid, Dimethyl Dioctadecyl Ammonium Bromide, on the Induction of Delayed-Type Hypersensitivity to Sheep Red Blood Cells in Mice'. * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963557A (en) * | 1987-09-28 | 1990-10-16 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
US5358944A (en) * | 1990-09-19 | 1994-10-25 | American Home Products Corporation | Rapamycin esters for treating transplantation rejection |
US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
WO1992022294A1 (en) * | 1991-06-07 | 1992-12-23 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
US5591748A (en) * | 1991-06-07 | 1997-01-07 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
US5434160A (en) * | 1992-11-18 | 1995-07-18 | Lilly Industries Limited | Pyrano[3,2-h]quinolines for treating restenosis |
US6121270A (en) * | 1992-12-16 | 2000-09-19 | Cell Therapeutics, Inc. | Epoxide-containing compounds |
WO1994016686A1 (en) * | 1993-01-27 | 1994-08-04 | Naturwissenschaftliches Und Medizinisches Institut An Der Universität Tübingen In Reutlingen | Wide spectrum antiviral chemotherapeutic agent and use thereof |
US7417031B2 (en) * | 1997-11-11 | 2008-08-26 | Takara Bio Inc. | Use of algae-derived physiologically active substances for treating a carcinomatous disease |
US6858623B2 (en) * | 2000-09-08 | 2005-02-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cysteine proteases |
US7648966B2 (en) * | 2003-05-20 | 2010-01-19 | Pharmaxis Pty Limited | Mannose-6-phosphonate compounds for the treatment of inflammatory diseases |
US8557794B2 (en) * | 2003-10-24 | 2013-10-15 | N.V. Nutricia | Immunemodulating oligosaccharides |
US7935672B2 (en) * | 2004-03-11 | 2011-05-03 | Michel Prost | Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same |
US8541182B2 (en) | 2004-12-02 | 2013-09-24 | Can-Fite Biopharma Ltd. | Biological marker for inflammation |
US8722645B2 (en) | 2006-05-16 | 2014-05-13 | Galectin Therapeutics Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
US8883746B2 (en) * | 2006-12-30 | 2014-11-11 | Snu R&Db Foundation | α-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient |
US20100104590A1 (en) * | 2006-12-30 | 2010-04-29 | Snu R&Db Foundation | Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient |
US9649327B2 (en) | 2011-12-28 | 2017-05-16 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US8962824B2 (en) | 2011-12-28 | 2015-02-24 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US8871925B2 (en) * | 2011-12-28 | 2014-10-28 | Galectin Therapeutics Inc. | Compositions of novel carbohydrate drug for treatment of human diseases |
US9974802B2 (en) | 2011-12-28 | 2018-05-22 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US20180256626A1 (en) * | 2011-12-28 | 2018-09-13 | Galectin Therapeutics, Inc. | Composition of Novel Carbohydrate Drug for Treatment of Human Diseases |
US10420793B2 (en) | 2011-12-28 | 2019-09-24 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US10799525B2 (en) | 2011-12-28 | 2020-10-13 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US11413303B2 (en) | 2011-12-28 | 2022-08-16 | Galectin Therapeutics, Inc. | Methods for treatment of arthritis |
US9763974B2 (en) | 2012-06-06 | 2017-09-19 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
US9872909B2 (en) | 2012-09-17 | 2018-01-23 | Galeotin Therapeutics, Inc. | Method for enhancing specific immunotherapies in cancer treatment |
US10398778B2 (en) | 2012-09-17 | 2019-09-03 | Galectin Therapeutics, Inc. | Method for enhancing specific immunotherapies in cancer treatment |
US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
Also Published As
Publication number | Publication date |
---|---|
EP0181351A4 (en) | 1989-06-21 |
JPS61502124A (en) | 1986-09-25 |
EP0181351A1 (en) | 1986-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1985005031A1 (en) | A method for the modulation of the immune response | |
Artzt et al. | Surface antigens common to mouse cleavage embryos and primitive teratocarcinoma cells in culture | |
US6019982A (en) | Mutant enterotoxin effective as a non-toxic oral adjuvant | |
KR940001373B1 (en) | Process for preparing influenza vaccine | |
EP0825875B1 (en) | Therapeutic composition comprising an antigen or an in vivo generator for generating a compound comprising an amino acid sequence | |
JP2003502388A5 (en) | ||
EP1232249A1 (en) | Duck pneumovirus and corresponding vaccines | |
TW577746B (en) | Method to produce inactivated w/o emulsion adjuvated vaccines | |
EP0681470B1 (en) | Recombinant living subunit vaccine composition and process for its preparation | |
FR2577139A1 (en) | VACCINE COMPOSITION AND METHOD OF PREPARATION | |
US5045320A (en) | Large multivalent immunogen | |
Charlemagne | Thymus independent anti-horse erythrocyte antibody response and suppressor T cells in the Mexican axolotl (Amphibia, Urodela, ambystoma mexicanum). | |
Goodman et al. | Manifold amplification of in vivo immunity in normal and immunodeficient mice by ribonucleosides derivatized at C8 of guanine. | |
Ashman et al. | Immunosuppressive effects of cationic vesicles | |
JP2001515869A (en) | Mucosal cytotoxic T lymphocyte response | |
Ferber et al. | The generation of monoclonal antibodies in mice: influence of adjuvants on the immune response, fusion efficiency and distress | |
Berman et al. | Tumors and immunological response in rhesus monkeys born after in utero inoculation with Rous sarcoma virus | |
Burrows | Toward an effective prophylactic immunity to cholera | |
Rollwagen | Role of natural killer cells in the early clearance of Rickettsia typhi in mice | |
EP0937389A2 (en) | Scid mouse having a normal immun response to exogenous antigens | |
US20020048587A1 (en) | Sugar ethers as adjuvants in immunization compositions | |
Hanly et al. | Information Resources for Adjuvants and Antibody Production: Comparisons and Alternative Technologies | |
FR2692149A1 (en) | Adjuvant composition of humoral and cell-mediated immunity not inducing response to auto-antigenic determinants. | |
WO2005115412A2 (en) | Compositions and methods for modulating an immune response | |
JP2010540487A (en) | Vaccine for the treatment of osteoarthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU JP US |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1985901941 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1985901941 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1985901941 Country of ref document: EP |